Abrdn Life Sciences Investors (NYSE:HQL – Get Free Report) saw a large decrease in short interest during the month of September. As of September 15th, there was short interest totalling 154,100 shares, a decrease of 10.8% from the August 31st total of 172,800 shares. Based on an average daily volume of 95,000 shares, the days-to-cover ratio is currently 1.6 days.
Abrdn Life Sciences Investors Stock Down 0.3 %
NYSE:HQL opened at $14.95 on Friday. The firm’s fifty day moving average is $15.23 and its 200-day moving average is $14.25. Abrdn Life Sciences Investors has a 52 week low of $11.34 and a 52 week high of $15.90.
Abrdn Life Sciences Investors Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Friday, August 23rd will be paid a $0.49 dividend. This is a positive change from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.48. This represents a $1.96 dividend on an annualized basis and a dividend yield of 13.11%. The ex-dividend date of this dividend is Friday, August 23rd.
Institutional Inflows and Outflows
Abrdn Life Sciences Investors Company Profile
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.
Read More
- Five stocks we like better than Abrdn Life Sciences Investors
- Health Care Stocks Explained: Why You Might Want to Invest
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- Options Trading – Understanding Strike Price
- CarMax’s Impressive Rally: What Investors Should Watch Next
- 3 Fintech Stocks With Good 2021 Prospects
- MarketBeat Week in Review – 9/23 – 9/27
Receive News & Ratings for Abrdn Life Sciences Investors Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abrdn Life Sciences Investors and related companies with MarketBeat.com's FREE daily email newsletter.